Michael R. Megna Sells 9,051 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna sold 9,051 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at approximately $595,553.60. This represents a 25.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kiniksa Pharmaceuticals Trading Up 2.0 %

KNSA stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The business’s 50 day simple moving average is $19.99 and its 200 day simple moving average is $22.16. The firm has a market capitalization of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same quarter last year, the business earned $0.35 earnings per share. The company’s revenue was up 46.9% on a year-over-year basis. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $268,000. Segall Bryant & Hamill LLC bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at about $675,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Kiniksa Pharmaceuticals by 40.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock valued at $8,098,000 after buying an additional 92,985 shares in the last quarter. Cerity Partners LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $834,000. Finally, Algert Global LLC boosted its position in shares of Kiniksa Pharmaceuticals by 390.0% during the 3rd quarter. Algert Global LLC now owns 91,159 shares of the company’s stock worth $2,278,000 after acquiring an additional 72,556 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on KNSA shares. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $40.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.